Teva Pharmaceutical Industries Limited (TEVA), a pharmaceuticals company, on Friday announced new IMPACT-TD and RIM-TD data evaluating AUSTEDO and AUSTEDO XR in treating Tardive dyskinesia. The data was presented at the Psych Congress Elevate conference.
Tardive dyskinesia (TD) is a debilitating, chronic movement disorder affecting one in four people who take certain mental health treatments. It is characterized by uncontrollable, abnormal, repetitive movements of the face, torso, and other body parts.
AUSTEDO (deutetrabenazine) and AUSTEDO XR (deutetrabenazine extended release) are vesicular transporter 2 (VMAT2) inhibitors, and received FDA approval in 2017 and 2023, respectively. They are used to treat tardive dyskinesia and chorea associated with Huntington's disease.
IMPACT-TD is the largest real-world study of TD and evaluated patients with mild symptoms beginning AUSTEDO or AUSTEDO XR therapy. After three months, participant showed an improvement on the Abnormal Involuntary Movement Scale (AIMS) scale while maintaining their psychiatric stability.
The three-year, open-label RIM-TD study found that patients showed long-term responses on sustained treatment. More than 50% showed AIMS improvement within 15 weeks, and an additional 23% saw improvement after week 15.
The study found that with greater caregiver education and awareness raised through online platforms, diagnosis of TD increased significantly.
TEVA is currently trading at $34.43, up 0.53%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.